Skip to content
Peptide research

Humanin

Also known as HN Peptide
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
Not FDA-approved

A 24-amino-acid peptide encoded by mitochondrial DNA, marketed for neuroprotection, metabolic support, and longevity. The evidence is almost entirely cell and animal work; there are no controlled human trials and essentially no human safety data. Its anti-apoptotic, STAT3-driven mechanism raises an unresolved concern about promoting existing cancers. Not an approved drug in the US, and supply is unregulated research-grade material of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Humanin is a small 24-amino-acid peptide naturally produced by your mitochondria (the energy-producing structures inside every cell). Discovered in 2001 from the brain tissue of an Alzheimer's patient, it was the first peptide found to be encoded by mitochondrial DNA — a discovery that opened an entirely new field of biology. Named to reflect its potential to 'restore humanity' in Alzheimer's patients, humanin is a powerful cell-protective factor found in the heart, kidneys, liver, brain, and skeletal muscle. Its levels decline with age in mice, monkeys, and humans, but remain significantly elevated in centenarians and their children, suggesting a direct link to longevity.

How it works in the body

A 24-amino-acid peptide encoded by mitochondrial DNA. It binds to the FPRL1 receptor and a trimeric receptor complex (CNTFR/WSX-1/gp130), activating STAT3 and ERK survival pathways. This protects cells — especially neurons — from programmed cell death triggered by amyloid-beta, oxidative stress, and other insults.

Research overview

Humanin is one of the most extensively studied mitochondrial-derived peptides, with over two decades of research across neuroprotection, metabolic health, cardiovascular protection, and aging biology. It works through multiple mechanisms: inside cells, it blocks programmed cell death, activates cellular cleanup processes, and reduces damaging free radicals; outside cells, it activates survival signaling pathways through specific receptors. Notably, humanin can directly interact with Alzheimer's-related amyloid proteins and convert them from toxic clumps into harmless forms. In worm models, boosting humanin extended lifespan. In mice, its potent synthetic analog HNG (1,000 times more active) improved memory in Alzheimer's models, reduced fat, and increased lean body mass in aged animals. All evidence comes from cell culture and animal studies — no human clinical trials have been completed as of early 2026.

Who researches Humanin?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Active cancer

    Moderate

    Humanin is anti-apoptotic — helps cells resist programmed death. May protect cancer cells from apoptosis in some contexts.

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data. Anti-apoptotic effects during fetal development are unpredictable.

Safety & interactions

Do not use if

  • Active cancer

    Moderate

    Humanin is anti-apoptotic — helps cells resist programmed death. May protect cancer cells from apoptosis in some contexts.

General cautions

  • Pregnancy

    Absolute

    No human reproductive safety data. Anti-apoptotic effects during fetal development are unpredictable.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • No controlled human clinical trials; all safety from preclinical

    High

    PMC10135985 (systematic review); AJP-Endo 2020, doi:10.1152/ajpendo.00249.2020

  • Anti-apoptotic mechanism (Bax inhibition) may facilitate tumor progression in some cancers

    Moderate

    Nature Sci Rep 2020, PMC7244539 / s41598-020-65381-7

  • Signals through STAT3, implicated in cancer progression

    Moderate

    PMC7244539 (TNBC/STAT3); PMC10135985 (STAT3 receptor signaling)

  • Transgenic humanin mice showed 46.5% decrease in litter size

    Low

    PMC7343442 / Aging 2020, article 103534

  • Transgenic humanin mice showed 12% decrease in body length / 10.4% lower body weight

    Low

    PMC7343442 / Aging 2020, article 103534

  • Injection site irritation (community reports)

    Low

    Anecdotal community reports; no peer-reviewed source located

Interaction summary(5)

Rated by direction with this peptide

  • Cytotoxic chemotherapy (antitumor efficacy) - e.g. doxorubicin, paclitaxel, cisplatin

    CautionModerate

    In TNBC-bearing mice, systemic humanin blunted chemotherapy's antitumor and anti-metastatic effect and accelerated tumor progression, so concurrent use in active cancer could protect tumor cells and reduce chemo efficacy. In-vivo demonstrated; human relevance not quantified.

    Nature Sci Rep 2020, PMC7244539

  • Chemotherapy-induced organ & germ-cell toxicity (cyclophosphamide, doxorubicin, cisplatin)

    ProtectiveLow

    Opposite context to tumor cells: humanin/analogs reduced cyclophosphamide- and doxorubicin-induced male germ-cell apoptosis and preserved cardiomyocyte mitochondrial integrity, i.e. protected normal tissue from chemo toxicity in preclinical models. Primary support is the peer-reviewed Apoptosis 2015 germ-cell study; the cited US Patent 10792331 is non-peer-reviewed and treated as weak, corroborating-only.

    Apoptosis 2015, doi:10.1007/s10495-015-1105-5 (primary); US Patent 10792331 (non-peer-reviewed, corroborating only)

  • Insulin / sulfonylureas / other glucose-lowering agents

    SynergisticTheoretical

    Preclinically humanin enhances insulin sensitivity, increases glucose uptake and suppresses hepatic glucose output, so it could add to glucose-lowering drugs; additive hypoglycemia in humans is unstudied but warrants monitoring (treat the same-direction effect as a hypoglycemia caution).

    PMC4873641; Frontiers Endocrinol 2021, doi:10.3389/fendo.2021.808120

  • Growth hormone / IGF-1 therapy

    CautionLow

    Humanin and IGF-1 reciprocally suppress each other (IGF-1 lowers plasma humanin and humanin lowers circulating IGF-1; inverse correlation in humans), so co-use may mutually blunt effects and humanin may oppose GH/IGF-1 anabolic signaling.

    PMC4172517 (IGF-I regulates humanin); PMC4961574 (humanin-IGF-I interfaces)

  • Metformin

    SynergisticTheoretical

    Indirect and unproven (two-step inference): metformin lowers IGF-1, and IGF-1 suppresses humanin, so metformin could plausibly raise endogenous humanin; the metabolic and anti-aging directions align, but no direct metformin-humanin interaction study exists.

    PMC4172517 (humanin-IGF-1 axis); metformin-IGF-1 meta-analysis, doi:10.1016/j.mad.2019.111143

Known risks(8)

  • Potential tumor promotion

    Humanin's anti-apoptotic mechanism (Bax inhibition) may facilitate tumor progression in certain cancers. Studies have observed pro-tumoral effects in triple-negative breast cancer, glioblastoma, and gastric cancer models. Suppressing humanin increased tumor apoptosis and reduced growth in these models.

  • No human safety data

    No controlled human clinical trials have been conducted. All safety information is derived from animal studies and anecdotal community reports. Long-term effects of exogenous humanin administration are unknown.

  • STAT3-mediated oncogenic potential

    Humanin signals through STAT3, a pathway implicated in cancer progression. Long-term exogenous administration could theoretically promote oncogenic signaling, though this has not been systematically studied.

  • Reproductive effects

    Transgenic humanin mice showed 46.5% decrease in litter size, suggesting potential effects on fertility or reproductive function.

  • Growth and development effects

    Transgenic humanin mice exhibited 12% decrease in body length and 10.4% reduction in body weight, suggesting potential effects on growth hormone/IGF-1 axis.

  • Injection site reactions

    Community reports indicate mild redness, swelling, and skin irritation at injection sites, described as short-lived.

  • Gastrointestinal symptoms

    Rare occurrences of nausea, vomiting, and mild diarrhea reported, typically limited to the first dose and resolving within hours.

  • Unstable peptide

    Humanin has stability challenges requiring specialized formulations (e.g., monoolein-based formulations) to maintain structure at physiological temperatures. Degradation products and their effects are not characterized.

Drug interactions(6)

  • IGF-1 / Growth Hormone axis modulators

    Theoretical/Moderate

    Humanin binds IGFBP-3 (insulin-like growth factor binding protein 3), preventing caspase activation. Concurrent use with GH or IGF-1 therapies may alter humanin's signaling dynamics and IGFBP-3 availability.

  • Chemotherapy agents (e.g., cyclophosphamide)

    Theoretical/High

    Humanin protects germ cells and lymphocytes from chemotherapy-induced apoptosis. While this could be beneficial for preserving healthy tissue, it could theoretically reduce chemotherapy efficacy against tumors by inhibiting Bax-mediated apoptosis in cancer cells.

  • Anti-cancer therapies targeting apoptosis

    Theoretical/High

    Humanin's Bax-inhibiting, anti-apoptotic mechanism directly opposes the mechanism of pro-apoptotic cancer therapies (e.g., BH3 mimetics like venetoclax). Concurrent use could reduce therapeutic efficacy.

  • JAK/STAT pathway inhibitors (e.g., tofacitinib, ruxolitinib)

    Theoretical/Moderate

    Humanin signals through STAT3 via the gp130 receptor complex. JAK/STAT inhibitors may attenuate humanin's cytoprotective signaling.

  • Insulin and diabetes medications

    Theoretical/Low-Moderate

    Humanin interacts with the insulin/IGF-1 signaling pathway and may modulate insulin sensitivity. Concurrent use with insulin or insulin sensitizers could potentially affect glycemic control.

  • MOTS-c and other mitochondrial-derived peptides

    As members of the same MDP family, co-administration of humanin with MOTS-c or SHLPs may have additive or synergistic effects on metabolic and cytoprotective pathways. No interaction data exists.

Research & benefits

Evidence base

Evidence Level
Preclinical only
Total Studies
200+ preclinical publications
Human Studies
0 completed clinical trials; observational biomarker studies only

All evidence for humanin comes from in vitro cell studies and animal models (C. elegans, mice, rats, primates). No completed human clinical trials exist as of March 2026. Observational human data shows reduced CSF humanin in Alzheimer's patients (n=3) and elevated circulating humanin in children of centenarians. Naked mole-rats maintain stable humanin levels across their lifespan, unlike mice which show ~40% decline over 18 months.

Researched for(8)

Rated by confidence in the evidence

  • Neuroprotection against Alzheimer's disease pathology

    Medium

    Consistent animal and lab data show it shields neurons from Alzheimer's-related damage; no human trials yet.

    PMID 23496134 (review); PMC5562564 (rat Abeta model); Biology 2023, doi:10.3390/biology12121534

  • Cytoprotection from apoptosis and oxidative stress

    Medium

    Its most replicated effect, protecting many cell types from death and oxidative stress; still preclinical.

    PMC10135985 (systematic review); PMC8222669 (oxidative-stress mechanism); PMID 23985350 (mitochondrial integrity)

  • Diabetes and insulin signaling modulation

    Medium

    Animal studies plus human data linking lower humanin to impaired fasting glucose; no treatment trials yet.

    PMC4873641 (human impaired-fasting-glucose biomarker); PMC2709436 (Muzumdar central insulin action, PLoS ONE 2009); Frontiers Endocrinol 2021, doi:10.3389/fendo.2021.808120 (diabetes review)

  • Metabolic improvement and body composition

    Low

    Animal data suggest metabolic benefits, but body-composition effects in people remain unestablished.

    PMC7343442 / PMID 32575074 (HNG healthspan, mice); PMC4873641 (human biomarker)

  • Cardiovascular and cellular stress protection

    Low

    Animal and lab studies show reduced heart injury after ischemia; no human evidence yet.

    PMID 27434747 (cardiac I/R); PMC8222669 (aging CVD oxidative mechanism); PMID 23985350 (cardiac myoblasts)

  • Lifespan extension in model organisms

    Low

    Extends lifespan in C. elegans; in mammals only healthspan markers, reported by one research group.

    PMC7343442 / PMID 32575074 (Aging 2020, Cohen lab)

  • Protection against brain ischemia and traumatic brain injury

    Low

    Reduced stroke damage in mice; humanin treatment also improved cognition in a mouse traumatic brain injury model. No human treatment evidence.

    PMC2575816 (cerebral I/R, PI3K/Akt); Stroke 2006, doi:10.1161/01.STR.0000242772.94277.1f

  • Potential protection against age-related macular degeneration

    Speculative

    Only cell-culture evidence so far; no animal or human studies in macular degeneration.

    PMC5550888 (HNG AMD cybrids); PMC7767738 (RPE oxidant-injury review)

Benefits(8)

  • Neuroprotection against Alzheimer's disease pathology

    Multiple preclinical studies in APPswe/PS1dE9 and 3xTg-AD mouse models show HNG ameliorates spatial learning/memory deficits and decreases Aβ plaque accumulation (Karachaliou & Livaniou, Biology 2023)

  • Cytoprotection from apoptosis and oxidative stress

    Humanin inhibits Bax-mediated mitochondrial apoptosis, activates chaperone-mediated autophagy, reduces ROS, and restores mitochondrial glutathione (PMC7343442; PMC10740898)

  • Metabolic improvement and body composition

    Mid-life HNG treatment (4 mg/kg biweekly) in 18-month-old mice decreased visceral fat, increased lean body mass, and reduced IGF-I levels (Yen et al., Aging (Albany NY) 2020, PMC7343442)

  • Cardiovascular and cellular stress protection

    Transgenic humanin-overexpressing mice showed protection from cyclophosphamide-induced lymphocyte reduction and germ cell apoptosis (PMC7343442)

  • Lifespan extension in model organisms

    Humanin overexpression increased C. elegans lifespan from 17.7 to 19.0 days average via daf-16/FOXO-dependent mechanism (PMC7343442)

  • Protection against brain ischemia and traumatic brain injury

    HNG reversed cognitive impairment in mTBI models; colivelin (HN analog) decreased neurological deficits and infarct lesions in focal cerebral ischemia models (PMC10740898)

  • Potential protection against age-related macular degeneration

    Humanin has shown cytoprotective effects in experimental models of AMD through anti-apoptotic and antioxidant mechanisms (PMC10740898)

  • Diabetes and insulin signaling modulation

    Humanin interacts with the insulin/IGF-1 signaling pathway and has shown beneficial effects in diabetes models through IGFBP-3 binding and caspase inhibition (PMC8984571)

Key studies(7)

  1. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan

    Preclinical (C. elegans and mouse)Multiple cohorts of transgenic and wild-type animalsLifespan studies

    Yen K, Mehta HH, Kim SJ, et al.

    Aging (Albany NY)

    2020

    Humanin overexpression increased C. elegans lifespan via daf-16/FOXO. In aged mice, HNG (4 mg/kg biweekly) decreased visceral fat, increased lean mass, and reduced IGF-I without extending lifespan.

  2. Karachaliou CE, Livaniou E

    Biology (Basel)

    2023

    Comprehensive review of humanin's neuroprotective mechanisms including Bax inhibition, STAT3/ERK signaling, amyloid-beta interaction, and multiple analog developments. HNG is 1000-fold more potent than native humanin.

  3. Hazafa A, Batool A, Ahmad S, Amjad M, Chaudhry SN, Asad J, Ghuman HF, Khan HM, Naeem M, Ghani U

    Life Sciences

    2021

    Humanin protects multiple cell types from apoptosis via JAK/STAT pathway activation and BCL-2 family protein interaction. Demonstrates efficacy in models of cardiovascular disease, diabetes, and neurodegeneration.

  4. Lee C, Yen K, Cohen P

    Trends in Endocrinology & Metabolism

    2013

    Established humanin as the founding member of the mitochondrial-derived peptide family. Described its role as autocrine/paracrine/endocrine cytoprotective factor in cellular stress response.

  5. Niikura T

    Biochimica et Biophysica Acta – General Subjects

    2021

    Traced the discovery of humanin from the original 2001 screening of AD brain tissue. Described the evolution of research from neuroprotection to broad cytoprotective applications.

  6. Humanin P3S, haplogroup N1b and the risk of Alzheimer's disease

    CommentaryN/A — commentary on a separate genetic and experimental study

    Logan IS, et al.

    Aging Cell

    2024

    Identified that the mitochondrial DNA mutation m.C2639T (Humanin P3S variant) may be beneficial in people in haplogroup N1b who also carry APOE4, raising the possibility of therapeutic use of Humanin P3S in AD treatment.

  7. Zárate SC, Traetta ME, Codagnone MG, Seilicovich A, Reinés AG

    Frontiers in Aging Neuroscience

    2019

    Astrocyte-released humanin prevents synapse loss in hippocampal neurons, establishing a paracrine neuroprotective mechanism in the brain.

Regulation & availability

Why researchers look at it

Centenarians and their children carry significantly elevated levels of this mitochondrial peptide, while levels decline steadily with normal aging — and it was originally discovered in an Alzheimer's patient's brain tissue. A synthetic analog 1,000x more potent rescued memory in Alzheimer's mice, reduced body fat, and increased lean mass in aged animals. Separately, humanin overexpression extended lifespan in worms. All therapeutic evidence remains preclinical as of early 2026, and whether the animal findings apply to people is untested.

FDA status
Humanin is not FDA-approved and is not eligible for compounding in the US. No publicly confirmed IND or published human interventional treatment trial was identified. Human observational studies exist, but therapeutic efficacy and safety remain unestablished. No regulatory agency worldwide has approved humanin for any therapeutic indication.
WADA status
Humanin is not explicitly named on the 2026 WADA Prohibited List. As an unapproved pharmacological substance, exogenous therapeutic humanin should be treated as prohibited at all times under S0 unless another section applies. This classification follows S0's general rule and assumes no governmental approval for human therapeutic use.
Prescribability
No — Humanin is not FDA-approved and is not available by prescription. It remains an investigational research compound.
Availability
Humanin is not commercially available as a pharmaceutical product. Some peptide compounding services and wellness clinics may offer humanin or its analog HNG, but these are not regulated pharmaceutical products. The peptide can be chemically synthesized at large scale, in high yield, and at low cost, which is considered an advantage for future therapeutic development. No standardized pharmaceutical formulation exists. Administration in research settings has been via intraperitoneal, subcutaneous, intracerebral, intrahippocampal, and intranasal routes.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(9)

  1. 2001
    Discovery of Humanin from Alzheimer's disease brain tissue cDNA library by Hashimoto et al.
  2. 2003-2005
    Identification of key analogs including HNG (S14G, 1000x more potent) and Colivelin. Elucidation of CNTFR/WSX-1/gp130 trimeric receptor and STAT3 signaling.
  3. 2020
    Demonstration of lifespan extension in C. elegans and metabolic improvement in aged mice (PMC7343442).
  4. 2013
    Humanin recognized as founding member of the mitochondrial-derived peptide (MDP) family alongside MOTS-c and SHLPs (PMC3641182).
  5. 2019
    Demonstration that astrocyte-released humanin prevents synapse loss in hippocampal neurons, establishing paracrine neuroprotective mechanism.
  6. 2021
    Reviews published in Life Sciences and online in Biochimica et Biophysica Acta – General Subjects consolidate two decades of humanin research.
  7. 2023
    Major review by Karachaliou & Livaniou in Biology cataloging all humanin analogs, delivery systems, and identifying AI-assisted analog design as future direction.
  8. 2024
    Logan comments on a separate study of Humanin P3S, haplogroup N1b, longevity and APOE4-related pathology (Aging Cell).
  9. 2026 (current)
    No publicly confirmed IND or published human interventional treatment trial was identified. Observational human studies are registered. Humanin remains investigational.

Sources & FAQs

Research sources(9)

Frequently asked questions(6)

What is Humanin and where does it come from?

Humanin is a 24-amino acid peptide (sequence: MAPRGFSCLLLLTSEIDLPVKRRA) encoded by the mitochondrial genome within the 16S rRNA gene. It was first discovered in 2001 from brain tissue of an Alzheimer's disease patient. It is naturally produced by cells throughout the body and found in plasma, cerebrospinal fluid, and reproductive fluids.

How does Humanin protect cells?

Humanin works through multiple mechanisms: (1) it binds and inhibits the pro-apoptotic protein Bax, preventing cell death; (2) it activates chaperone-mediated autophagy to clear damaged proteins; (3) it reduces reactive oxygen species; (4) it signals through the CNTFR/WSX-1/gp130 receptor complex to activate STAT3; and (5) it directly interacts with amyloid-beta to prevent fibril formation.

What is HNG and how does it differ from native Humanin?

HNG (also called S14G-Humanin) is a synthetic analog where serine at position 14 is replaced with glycine. This single amino acid substitution makes HNG approximately 1000-fold more potent than native humanin in neuroprotective assays. Most animal studies use HNG rather than native humanin due to its superior efficacy.

Has Humanin been tested in humans?

No completed human clinical trials exist as of March 2026. All therapeutic evidence comes from cell culture and animal studies. However, observational human biomarker studies have shown that humanin levels in cerebrospinal fluid are reduced in Alzheimer's patients, and that children of centenarians have higher circulating humanin levels.

Does Humanin decline with aging?

Yes. Circulating humanin levels decrease with age in mice (approximately 40% decline over 18 months), monkeys, and humans. This age-related decline is associated with increased vulnerability to neurodegeneration and metabolic dysfunction. Notably, naked mole-rats — which are exceptionally long-lived — maintain stable humanin levels throughout their lifespan.

Is Humanin safe?

No formal human safety data exists. In animal studies, humanin transgenic mice showed decreased body length (12%), reduced body weight (10.4%), and reduced litter size (46.5%). A significant concern is that humanin may promote tumor growth in certain cancers, particularly triple-negative breast cancer, due to its anti-apoptotic mechanism. Community users report mild injection site reactions and occasional gastrointestinal symptoms.